Search results for

At a time when more women than men are graduating from college and earning doctorates, just a third of Ph.D.s in economics go to women. Now there's an effort to increase women economists at the Fed.

In the movies, "Mr. Smith" stands by his principles and prevails in the capital. In Cliff Sims's story, told in a new book, the hero descends into disillusionment — but not before enjoying the ride.

The soundtrack to the movie The Greatest Showman is outselling Kanye West, Taylor Swift and Justin Timberlake this year. Critic Rob Harvilla reviewed the album for The Ringer and explains its success.

Rachel Martin talks to Sen. Patrick Leahy of Vermont, the top Democrat on the Senate Appropriations Committee and one of four negotiators of the bipartisan border security compromise measure.

President Trump's impeachment and the Mueller investigation were the top news stories in 2019. We go over other stories from 2019 that deserve a second look.

Some pro-Trump news outlets are singling out federal employees and accusing them of trying to sabotage the president. The targets have often worked for decades in government outside of the spotlight.

Twelve Democratic presidential contenders took to the debate stage in Westerville, Ohio, Tuesday night. The issue of impeachment was at the top of the agenda.

It started as a joke, as President Trump riffed on the idea last year. Now, Congress could create the first, new military service in more than 70 years.

Since June, documents leaked by National Security Agency contractor Edward Snowden have produced revelation upon revelation about the nation's top-secret intelligence gathering operations. The latest information, about U.S. spying on foreign leaders, has angered even some dependable U.S. allies. New York Times national security reporter Scott Shane, and Sen. Ron Wyden, D-Ore., a senior member of the Senate Intelligence Committee, discuss the latest Snowden-related leaks.

In 2006, Oregon successfully made pseudoephedrine, a key ingredient of meth, a prescription drug. Since then, Mother Jones' Jonah Engle reports, 24 states have tried to follow suit — and 23 have failed. Engle attributes those failures to pharmaceutical companies' massive lobbying efforts.